1Fosslien E. Biochemistry of cyclooxygenase(COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lay Sci,2000, 37:431-502.
2Paik J, Lee JY, Hwang D. et al. Signaling pathways for TNF alpha-induced COX-2 expression: mediation through MAP kinases and NFkappaB, and inhibition by certain nonsteroidal anti-inflammatorydrugs. Adv Exp Med Biol, 2002, 507:503-508.
3Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology, 1999, 29:688-696.
4Coogan PF, Rosenberg L, Palmer JR, et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prey, 2000, 9:119-123.
5Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectalcancer. N Engl J Med, 2003, 348:883-890.
6Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med, 2000, 342: 1946-1952.
7Hu KQ. Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med,2002, 139:234-243.
8Souza RF, Shewmake K, Beer DG, et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res, 2000, 60:5767-5772.
9Dermott JM, Reddy MR, Onesime D, et al. Oncogenic mutant of Galphal2 stimulates cell proliferation through cyclooxygenase-2 signaling pathway. Oncogene, 1999, 18:7185-7189.
10Mann M, Sheng H, Shan J, et al. Targeting cyclooxygenase-2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology, 2001,120:1713-1719.
